Internal Medicine, Rheumatology · San Marcos, CA
NPI
1144455262
Since 2009
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
960 W San Marcos Blvd Ste 210
San Marcos, CA, 92078
Phone (760) 707-6765
Groups this clinician bills Medicare through
Medicare paid, 2024
$158K
13,043 services
Medicare patients, 2024
237
Average age 70
Drug cost, 2024
$2.9M
2,752 prescriptions
Company payments, 2025
$2,784
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Basma Al Nahlawi was code J1010 (injection, methylprednisolone acetate, 1 mg), 1,884 times for 23 patients. In total Basma Al Nahlawi billed 13,043 services in 25 codes, and Medicare paid $158K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-03-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 1,884 | 23 | $0.11 | $198 |
| 99214 Office E&M - Established | Office | 678 | 215 | $98.23 | $67K |
| 76881 Ultrasound - Nonspecific | Office | 251 | 106 | $41.50 | $10K |
| 99213 Office E&M - Established | Office | 127 | 103 | $73.93 | $9,390 |
| 99204 Office E&M - New | Office | 85 | 85 | $122.36 | $10K |
| 96372 Injection Administration | Office | 58 | 15 | $12.45 | $722 |
| 96413 Chemotherapy Administration | Office | 34 | 12 | $107.73 | $3,663 |
| 20611 Joint Injection | Office | 21 | 14 | $73.57 | $1,545 |
By year: 2022 $60K for 1,242 services; 2023 $145K for 18,189 services; 2024 $158K for 13,043 services.
Medicare prescription drug claims, 2024
In 2024, the drug Basma Al Nahlawi prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 701 prescriptions and refills. In total Basma Al Nahlawi wrote 2,752 Medicare prescriptions that cost $2.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 701 | 927 | 177 | $26K |
| Methotrexate Methotrexate Sodium | 305 | 483 | 93 | $7,011 |
| Prednisone Generic | 281 | 302 | 108 | $1,095 |
| Allopurinol Generic | 181 | 367 | 53 | $1,562 |
| Leflunomide Generic | 153 | 250 | 49 | $6,967 |
| Folic Acid Generic | 131 | 254 | 42 | $1,096 |
| Meloxicam Generic | 118 | 147 | 36 | $405 |
| Humira(Cf) Pen Adalimumab | 63 | 63 | Under 11 | $444K |
| Diclofenac Sodium Generic | 57 | 58 | 25 | $976 |
| Methylprednisolone Generic | 49 | 49 | 37 | $396 |
| Orencia Clickject Abatacept | 44 | 44 | Under 11 | $253K |
| Benlysta Belimumab | 44 | 44 | Under 11 | $139K |
| Prolia Denosumab | 34 | 204 | 25 | $60K |
| Teriparatide Generic | 33 | 33 | Under 11 | $117K |
| Taltz Autoinjector Ixekizumab | 29 | 29 | Under 11 | $194K |
Brand drugs: 460 claims; generic drugs: 2,281 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Basma Al Nahlawi $2,784 ($2,784 in general payments such as food, travel and fees) from 16 companies. The largest payer was Amgen Inc. with $729.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 43 | $729 |
| Abbvie Inc. ABBV | 28 | $584 |
| Novartis Pharmaceuticals Corporation NVS | 13 | $360 |
| Janssen Biotech, Inc. JNJ | 14 | $194 |
| ANI Pharmaceuticals, Inc. ANIP | 7 | $185 |
| UCB, Inc. UCB.BR | 5 | $169 |
| GlaxoSmithKline, LLC. GSK | 5 | $112 |
| Aurinia Pharma U.S., Inc. AUPH | 4 | $91.81 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $78.7 |
| Lilly USA, LLC LLY | 3 | $76.61 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.